Introduction {#S1}
============

Coronary artery disease (CAD) is the main cause of cardiovascular death worldwide ([@B47]) including United States ([@B6]), Europe ([@B72]), and Iran ([@B27]). CAD is characterized by atherosclerosis in the pericardial coronary arteries. Atherosclerotic plaques can cause narrowing or blockage of coronary arteries and reducing blood flow and oxygen to the heart muscle ([@B12]). Coronary artery bypass graft (CABG) surgery is one of the major treatment strategies for severe CAD ([@B79]); it is a surgical procedure to relieve angina ([@B62]). The aims of CABG surgery are to reduce previous symptoms of patients with coronary disease such as discomfort from chest pain ([@B79]), reduce the risk of heart attack, increase patient's chance of living longer ([@B26]) and improve quality of life (QoL) ([@B31]; [@B49]; [@B32]). World Health Organization (WHO) defines QoL as "the individual's perception of his/her position in life, within the cultural context and the values in which he/she lives, as well as relation to his/her objectives, expectations, standards and concerns." Thus, according to WHO, QoL includes of mental, physical and social well-being ([@B70]). Therefore, the importance of the health-related QoL is significant in patients after the CABG surgery ([@B37]).

Beside all the benefits from CABG surgery, there are some evidences indicating that QoL is lower in patients after CABG surgery than healthy population ([@B40]; [@B8]; [@B55]). CABG surgery has different negative side effects. It is often associated with systemic inflammatory response and dysfunction of several organs, including brain; diffuse cerebral injury after CABG surgery may result in cognitive deficits ([@B36]). Also, some studies have shown that cerebral hypoperfusion occurs after cardiac surgery ([@B29]), and it seems that there is relation between cerebral hypoperfusion and attention functions ([@B15]).

Many previous studies have shown that cognitive deficits following CABG surgery include memory, attention, (psycho) motor speed, and visuospatial ability ([@B66]; [@B25]; [@B45]; [@B10]; [@B21]). Selective and sustained attention and working memory decline are the most common cognitive deficits after CABG surgery and have been reported within 10 days after surgery ([@B71]; [@B76]; [@B35]). Cognitive deficits have been recognized as a significant complication after CABG surgery ([@B45]) and a risk factor for reduction in clinical health ([@B33]). Cognitive deficits after CABG surgery have been associated with delayed postoperative recovery ([@B41]), loss of independence, delayed return to work and impaired QoL ([@B9]). The prevalence of short-term cognitive deficits (\<2 weeks after surgery) has been estimated in 30--80% and long-term cognitive deficits (more than a month after surgery) in 10--60% of the patients ([@B56]). Cognitive deficits can lead to significant damage to QoL in CABG patients after surgery ([@B34]; [@B51]) by increasing risk for unemployment ([@B34]), hindering abilities to maintain social roles at a desirable level and poor function in daily life activities ([@B48]).

The association between cognitive deficits and QoL has been studied among different groups of patients including Alzheimer's disease (AD), Parkinson's disease, traumatic brain injury (TBI), and multiple sclerosis (MS) ([@B2]; [@B38]; [@B7]; [@B11]). Previous studies have stated that cognitive deficits influence QoL by affecting the cognitive functions (such as memory) and reducing the learning skills and social and occupational performances ([@B4]; [@B46]).

However, despite all efforts made in the field of routine cardiac rehabilitation (RCR) (including medical evaluation, exercise training, cardiac risk factor, education and counseling) to improve the QoL ([@B28]; [@B69]; [@B1]), some studies have stated that the proportion of patients who suffer from neurological complications has not changed and their QoL has not improved after RCR ([@B51]; [@B16]). So we need a treatment that specifically focuses on cognitive deficits. Cognitive rehabilitation therapy (CRT) has a long and successful history in the field of TBI, schizophrenia and AD ([@B61]; [@B74]; [@B14]). CRT is the science of compensating cognitive processing; it can result to the molecular and cellular recovery rehabilitation by integrating the behavioral and cognitive changes ([@B81]). CRT is used to improve cognitive functions including attention, memory and decision-making ([@B58]). CRT consists of two components: restorative exercises and compensatory strategies ([@B63]). The aim of restorative exercise is to restore the impaired cognitive functions by using computerized or paper-pencil exercises. While, the aim of compensatory strategy is to train patients how to use external tools to compensate their cognitive impairments ([@B5]). Computerized training programs have several advantages over paper-based training tools. For example, they can increase patient's motivation for treatment because of direct feedback and reducing treatment duration ([@B80]; [@B52]).

There is a study that has investigated the efficacy of CRT as a treatment to improve cognitive deficits after CABG surgery. Neuropsychological battery was used to assess cognitive changes following cardiac surgery. Training sessions included attention and working memory training tasks to improve divided attention and memory. Findings showed significant impact of trainings on attention and memory. Also, improvement of some cognitive functions that were not trained during intervention was reported ([@B17]). But, some questions have remained unanswered. For example, it is still unclear if improving cognitive functions would lead to improving QoL in CABG patients after surgery or not.

Therefore, the present study has been conducted to assess the efficacy of using computerized cognitive rehabilitation therapy (CCRT) as a supplementary treatment to RCR in patients after CABG surgery in terms of both cognitive functioning and QoL. Although there are some studies that have suggested another strategies to improve QoL in CABG patients such as optimizing patients' expectations ([@B60]), the hypothesis of this study was that patients who receive RCR plus CCRT would show greater improvement in cognitive functions and QoL than those who receive RCR plus sham version of CCRT and who receive RCR without any cognitive intervention.

Materials and Methods {#S2}
=====================

Participants {#S2.SS1}
------------

In this experimental study, a three-armed interventional trial with pre-, post-, and follow-up assessments in CCRT, active control and control groups was conducted. This study was a single blind trial in which 75 patients (male = 50 and female = 25) enrolled after CABG surgery between October 2017 and September 2018 in Tehran Heart Center. Allocation was carried out by the patient enrolment date (the first month = CCRT group, the second month = active control group, and the third month = control group). Before starting RCR, general assessment of patients (including demographic and clinical data) was recorded and patients completed the QoL questionnaire (SF-36), then baseline assessment of cognitive functions was done using Continuous performance, Flanker, Useful Field of View, and Digit Span tests. During the intervention period, control group only received RCR, active control group received RCR plus sham version of computerized cognitive training program and CCRT group received RCR plus computerized cognitive training program.

Patients were included in the study if they were 40--80 years of age, scheduled for a first CABG surgery without concomitant surgery, capable of perception of the research purpose, able to give informed consent before any study, able to speak in Persian with study personnel, able to read and write and work with computer and participate in concurrent standard routine rehabilitation during the trial. Patients were excluded if they used any medications that could have any effect on the cognitive functions (all antihypertensives and diuretics, antidepressants and anticonvulsants), had previous or current drug or alcohol abuse and had a mental disorder (major depression, schizophrenia or bipolar disorder) due to their negative effects on cognitive functions ([@B77]; [@B67]; [@B64]) and QoL ([@B24]). It should be mentioned that a structured clinical interview was used to screen for mental disorders by a certified psychiatrist. This study was approved by Ethics Committee of the Iranian Ministry of Health (reference number: IR.ut.Rec.1395029) and the Iranian Registry of Clinical Trials (IRCT ID: IRCT2017022132704N1) (<https://irct.ir/trial/25408>).

Intervention {#S2.SS2}
------------

Patients in CCRT group received CCRT plus RCR. CCRT was conducted individually in 24, 20-min sessions within 8 weeks. The cognitive training program applied in this study was Maghzineh®; Maghzineh^®^ is a computerized training for cognitive rehabilitation that activates different cognitive functions including attention, working memory, and inhibition.

Maghzineh^®^ developed in 24 sessions. Generally the level of difficulty for each task increases gradually (see [Figure 1](#F1){ref-type="fig"}) but according to the patient's performance the pattern shown in [Figure 1](#F1){ref-type="fig"} might be modified.

![(Architecture) Graded schedule of computerized cognitive rehabilitation exercises for 24 sessions with Maghzineh®. Numbers indicate the level of difficulty of each session exercises (1 = the easiest level to 3 = the hardest level).](fpsyg-10-01759-g001){#F1}

Patients in the active control group received a sham version of CCRT plus RCR. The sham version involved the same training program as Maghzineh^®^ without adaptivity and the difficulty level remained constant across the entire intervention. Active control intervention was chosen to reduce the probable confounding effects of social interaction of the CCRT.

Patients in the control group received RCR without any cognitive intervention for 2 months.

Assessments {#S2.SS3}
-----------

Assessments were performed at three time points: pre-, post-intervention, and 6-month follow-up.

### Neuropsychological Assessments {#S2.SS3.SSS1}

Cognitive functions (including sustained, selective and divided attention and working memory) were evaluated by the following assessments:

1.  Continues Performance Test (CPT): This is a test to measure sustained attention which means the ability to keep attention focused over time ([@B42]). The version used in this study has 50 digits as stimulus in which 10 stimuli (20%) are targets. Display time of each stimulus was 150 ms and interval between stimuli was 200 and 500 ms, respectively. Patients were presented a simple set of visual stimuli (random digits from 1 to 9) in specific period of time and were asked to respond to target stimulus (9 number) as quickly as possible by pressing the space bar once. This test measures the time of the response as well as its accuracy.

2.  Flanker Test (FT): This test was designed in the early 1970s by Eriksen and Eriksen. The FT assesses the selective attention and response inhabitation ([@B18]). Selective attention allows to successfully focus on goal relevant information while inhibiting irrelevant information. As such selective attention is part of inhibitory control ([@B57]). In this study, patients were presented 80 sets of arrows as a stimulus (central arrow as target stimulus surrounded by other distractor arrows). In the first step, patients were asked to focus on the center of computer screen and press direction arrow on the keyboard of computer that its direction is the same as central arrow on the screen. In second step, patients were asked to press opposite direction arrow key with central arrow on the screen.

3.  Useful Field of View Test (UFoVT): UFoV is a test to assess divided attention ([@B23]). Patients had to detect, identify and localize briefly presented targets. The patients had to and perform the central and peripheral tasks concurrently. Patients were asked to identify the type of vehicle (truck or car) appeared in the center of the screen and the one displayed in the periphery of the screen at one of eight possible radial locations (0°, 45°, 90°, 135°, 180°, 225°, 270°, and 315°) around the center (It should be noted that the type of vehicle in the center and periphery were not necessarily the same).

4.  Digit Span Test (DST): The DST measures working memory and has two subsections: forward digit span (FDS) and backward digit span (BDS) ([@B20]). In the FDS subsection, patients were presented with a series of digits on the computer screen; each trial includes a sequence of digits (varied from 2--8) flashing at once. Patients were asked to repeat the sequence in the same order, immediately after presentation. A correct response increases the length of the subsequent list by one digit, while two sequential incorrect responses end up the test. In the BDS, the patient was asked to choose the sequence in reverse order.

### Quality of Life Assessment {#S2.SS3.SSS2}

QoL Short Form (SF-36) questionnaire: This test was designed in the 1992s by Ware and Sherbourne. The SF-36 questionnaire asks 36 questions related to an individual's functional health and well-being ([@B75]). The SF-36 assesses eight aspects of QoL, including physical functioning (PF), role physical (RP), bodily pain (BP), general health (GH), vitality (VT), social functioning (SF), role emotional (RE), and mental health (MH) ([@B54]). Scores were calculated for each of these different aspects of health in the range 0--100, low score indicating poor health status ([@B68]). The reliability of the Persian version of this questionnaire has been confirmed by using Cronbach's alpha from 0.77 to 0.90 ([@B44]).

### Clinical Assessments {#S2.SS3.SSS3}

After admission, the cardiac rehabilitation team including doctors, nurses, nutritionists and mental health specialists recorded demographic and clinical data (Diabetic Mellitus, Hypertension, Family History, and Hyperlipidemia). Since many evidences suggested that patients experience depression, anxiety and stress after CABG surgery ([@B73]; [@B13]), the DASS scale was used for comparison of groups in baseline. In a study conducted in Iran with 378 non-clinical adults, Cronbach's alpha for Depression, Anxiety and Stress scales were 0.85, 0.85, and 0.87, respectively ([@B3]).

Statistical Analysis {#S2.SS4}
--------------------

Based on a *p*-value of 0.05, an expected drop-out from assessments of 50%, the study had a power of 80%, and an effect size of 0.25 (medium), a group of 75 subjects defined as a sample size. Descriptive statistics were used to describe the baseline characteristics of participants. Kruskal--Wallis *H* test was conducted to assess baseline differences of non-parametric characteristics of patients in three groups, analysis of variance (ANOVA) was used for parametric characteristics. Also, analysis of correlation was used to assess relationship between QoL and cognitive functions in baseline among all participants. The assumption of normal distribution of all parameters was examined with Kolmogorov--Smirnov, as a result the significance level of all parameters was ≥0.05, indicating a normal distribution. Repeated ANOVAs were performed to evaluate the effect of group (CCRT vs. control vs. active control), time (T0 vs. T1 vs. T2) and the time by group interaction, including only patients who accomplished the whole clinical trial according to the protocol. To estimate the effect size of intervention, partial eta squared values ($\eta_{p}^{2}$) were used and Pearson correlation analysis was conducted to illuminate the relationship between QoL improvement and cognitive functions enhancement among all participants. The QoL improvement and cognitive functions enhancement were calculated by subtracting the scores of QoL and cognitive functions in pre from Follow-up assessment. Where significant effects were found, pairwise comparison were carried out using the Bonferroni correction. Results of the *post hoc* comparison were presented as mean difference (MD) with 95% confidence interval (CI) and standard error (SE). Finally, an expectation maximization (EM) algorithm was performed to take the missing data into account. All statistical analysis was performed using SPSS v.23.0. Data for this study is pre-registered and accessible on Open Science Framework (OSF), titled "Efficacy of Neurocognitive Rehabilitation After Coronary Artery Bypass Graft Surgery in Improving Quality of Life." <https://osf.io/m249v>.

Results {#S3}
=======

Baseline Characteristics {#S3.SS1}
------------------------

Patient flow is presented in [Figure 2](#F2){ref-type="fig"}. A total of 75 participants after CABG surgery were registered and assigned 1:1:1 to CCRT, active control and control groups.

![CONSORT flow diagram of patients through the study.](fpsyg-10-01759-g002){#F2}

Baseline analysis showed no significant difference in terms of demographic variables (*p* \> 0.05), clinical variables (*p* \> 0.05), cognitive functions (*p* \> 0.05), and QoL (*p* \> 0.05) measures between the three groups ([Table 1](#T1){ref-type="table"}) and there was no significant correlation between QoL and cognitive functions among all participants (sustained attention: Pearson's *r* = 0.00, *p* = 0.958; selective attention: Pearson's *r* = 0.11, *p* = 0.331; divided attention: Pearson's *r* = 0.03, *p* = 0.781; working memory: Pearson's *r* = 0.08, *p* = 0.488). In addition, a comparison of completers and drop-outs in all three groups found no baseline difference in the demographical and clinical characteristics of those assigned to intervention.

###### 

Demographics, clinical variables and baseline scores of cognitive measures and QoL questionnaire in CCRT, control and active control groups.

  **Components**                  **CCRT group (*n* = 25)**   **Control group (*n* = 25)**   **Active Control group (*n* = 22)**   ***P*-value**                
  ------------------------------- --------------------------- ------------------------------ ------------------------------------- --------------- ------------ ------------
  Age mean (SD)                                               56.96 (15.20)                  56.48 (12.73)                         57.95 (9.76)    *p* = 0.94   
  Sex *n* (%)                     Male                        15 (60)                        20 (80)                               14 (63.6)       *p* = 0.28   
                                  Female                      10 (40)                        5 (20)                                8 (36.4)                     
  Education *n* (%)               Primary school              5 (20)                         8 (32)                                7 (31.8)        *p* = 0.56   
                                  High school                 14 (56)                        10 (40)                               12 (54.5)                    
                                  University                  6 (24)                         7 (28)                                3 (13.6)                     
  Marital status *n* (%)          Single                      3 (12)                         3 (12)                                3 (13.6)        *p* = 0.98   
                                  Married                     22 (88)                        22 (88)                               19 (86.4)                    
  DM *n* (%)                      Yes                         8 (32)                         14 (56)                               6 (27.3)        *p* = 0.09   
                                  No                          17 (68)                        11 (44)                               16 (72.7)                    
  HTN *n* (%)                     Yes                         8 (32)                         9 (36)                                6 (27.3)        *p* = 0.82   
                                  No                          17 (68)                        16 (64)                               16 (72.7)                    
  FH *n* (%)                      Yes                         2 (8)                          7 (28)                                6 (27.3)        *p* = 0.15   
                                  No                          23 (92)                        18 (72)                               16 (72.7)                    
  HLP *n* (%)                     Yes                         4 (16)                         8 (32)                                3 (13.6)        *p* = 0.23   
                                  No                          21 (84)                        17 (68)                               19 (86.4)                    
  Obesity *n* (%)                 Yes                         3 (12)                         1 (4)                                 0               *p* = 0.19   
                                  No                          22 (88)                        24 (96)                               22 (100)                     
  Personality *n* (%)             Type A                      17 (68)                        22 (88)                               14 (63.6)       *p* = 0.12   
                                  Type B                      8 (32)                         3 (12)                                8 (36.4)                     
  Smoker *n* (%)                  Yes                         5 (20)                         7 (28)                                4 (18.2)        *p* = 0.69   
                                  No                          20 (80)                        18 (72)                               18 (81.1)                    
  DASS                            Depression *n* (%)          Normal                         15 (60)                               13 (52)         10 (45)      *p* = 0.38
                                                              Mild                           1 (40)                                2 (8)           2 (9.1)      
                                                              Moderate                       6 (24)                                8 (32)          3 (13.6)     
                                                              Severe                         3 (12)                                0               3 (13.6)     
                                                              Extremely severe               0                                     2 (8)           4 (18.2)     
                                  Anxiety *n* (%)             Normal                         11 (44)                               9 (36)          7 (31.8)     *p* = 0.51
                                                              Mild                           3 (12)                                5 (20)          4 (18.2)     
                                                              Moderate                       7 (28)                                2 (8)           3 (13.6)     
                                                              Severe                         1 (4)                                 5 (20)          2 (9.1)      
                                                              Extremely severe               3 (12)                                4 (16)          6 (27.3)     
                                  Stress *n* (%)              Normal                         11 (44)                               9 (36)          11 (50)      *p* = 0.55
                                                              Mild                           3 (12)                                4 (16)          1 (4.5)      
                                                              Moderate                       7 (28)                                9 (36)          1 (4.5)      
                                                              Severe                         1 (4)                                 2 (8)           6 (27.3)     
                                                              Extremely severe               3 (12)                                1 (4)           3 (13.6)     
  Cognitive functions mean (SD)   Continues performance       58.74 (9.39)                   59.58 (10.88)                         65.25 (10.66)   *p* = 0.07   
                                  Flanker                     84.90 (13.58)                  81.74 (16.44)                         82.72 (13.24)   *p* = 0.73   
                                  Useful field of view        86.86 (11.77)                  89.21 (11.81)                         81.20 (16.04)   *p* = 0.11   
                                  Forward digit span          73.96 (8.12)                   73.76 (9.60)                          70.18 (10.90)   *p* = 0.32   
                                  Backward digit span         66.52 (13.46)                  67.72 (7.66)                          64.95 (6.64)    *p* = 0.63   
  QoL mean (SD)                   53.48 (12.21)               49.70 (18.38)                  44.22 (18.29)                         *p* = 0.26                   

No significant differences between groups were observed. DM = Diabetic Mellitus; HTN = Hypertension; FH = Family History; HLP = Hyperlipidemia; DASS = Depression Anxiety Stress Scales.

Primary Outcomes in Final Assessment {#S3.SS2}
------------------------------------

The repeated ANOVA was carried out; in the [Table 2](#T2){ref-type="table"} the main effect of time, intervention and time by group interaction as well as mean scores corresponding to time points is presented. Furthermore in the [Table 3](#T3){ref-type="table"} pairwise comparison results are reported according to Bonferroni correction.

###### 

Summary of pre- and post-intervention and 6-month follow-up measures and significant interaction on repeated ANOVA.

  **Components**        **CCRT group (*n* = 14)**   **Control group (*n* = 11)**   **Active Control group (*n* = 10)**   **Intervention F (*p*) \[$\eta_{p}^{2}$\]**   **Time F (*p*) \[$\eta_{p}^{2}$\]**   **Intervention × time *F* (*p*) \[$\eta_{p}^{2}$\]**                                                                   
  --------------------- --------------------------- ------------------------------ ------------------------------------- --------------------------------------------- ------------------------------------- ------------------------------------------------------ --------- --------- --------- ---------------- ---------------- ----------------
  Sustained attention   57.36                       72.32                          71.20                                 58.60                                         69.14                                 61.21                                                  64.66     62.26     62.55     0.92             10.85            6.77
                        (10.37)                     (9.08)                         (10.01)                               (8.78)                                        (6.54)                                (14.03)                                                (11.02)   (9.12)    (9.75)    (*p* = 0.406)    (*p* \< 0.001)   (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.05\]         \[0.25\]         \[0.29\]
  Selective attention   83.21                       99.19                          98.28                                 81.45                                         85.83                                 84.63                                                  85.25     83.00     82.50     2.96             7.25             6.72
                        (16.81)                     (0.79)                         (1.54)                                (20.21)                                       (16.56)                               (15.93)                                                (9.57)    (11.16)   (11.67)   (*p* = 0.066)    (*p* = 0.008)    (*p* = 0.002)
                                                                                                                                                                                                                                                                                                  \[0.15\]         \[0.18\]         \[0.29\]
  Divided attention     84.99                       91.66                          98.07                                 88.98                                         86.36                                 87.63                                                  80.49     81.99     79.40     2.30             3.85             8.19
                        (13.44)                     (10.84)                        (2.16)                                (13.03)                                       (13.75)                               (11.64)                                                (18.77)   (14.67)   (16.47)   (*p* = 0.117)    (*p* = 0.043)    (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.12\]         \[0.10\]         \[0.33\]
  Working memory        69.53                       86.35                          84.96                                 69.68                                         67.95                                 64.13                                                  65.85     64.30     66.55     36.30            6.47             16.69
                        (7.93)                      (4.21)                         (6.10)                                (5.99)                                        (8.04)                                (6.66)                                                 (5.41)    (5.02)    (8.04)    (*p* \< 0.001)   (*p* = 0.003)    (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.69\]         \[0.16\]         \[0.51\]
  QoL                   48.03                       73.44                          74.10                                 45.20                                         53.52                                 55.01                                                  41.50     50.13     50.75     4.74             45.88            7.39
                        (17.69)                     (14.48)                        (12.90)                               (18.06)                                       (18.83)                               (13.98)                                                (20.98)   (14.90)   (13.20)   (*p* = 0.016)    (*p* \< 0.001)   (*p* = 0.001)
                                                                                                                                                                                                                                                                                                  \[0.22\]         \[0.58\]         \[0.31\]

Values represent mean scores (SD and

η

p

2

are between parenthesis and brackets respectively). Significant time by group interaction was observed. T0 = pre-intervention (week 0); T1 = post-intervention (week 8); T2 = 6-month follow-up (week 32).

###### 

Summary of *post hoc* analysis (Bonferroni correction).

  **Components**        **Groups**   **MD**           **SE**   ***p*-value**   **95% CI**             
  --------------------- ------------ ---------------- -------- --------------- ------------ --------- -------
  Sustained attention   CCRT         Control          3.97     3.33            0.72         --4.45    12.40
                                     Active control   3.80     3.43            0.82         --4.86    12.46
                        Control      Active control   --0.17   3.61            1.00         --9.31    8.97
  Selective attention   CCRT         Control          9.59     4.69            0.14         --2.27    21.45
                                     Active control   9.98     4.82            0.14         --2.20    22.17
                        Control      Active control   0.39     5.09            1.00         --12.47   13.25
  Divided attention     CCRT         Control          3.91     497             1.00         --8.65    16.49
                                     Active control   10.94    5.11            0.12         --1.97    23.87
                        Control      Active control   7.02     5.39            0.60         --6.60    20.66
  Working memory        CCRT         Control          13.02    1.90            0.00         8.21      17.84
                                     Active control   14.71    1.95            0.00         9.77      19.66
                        Control      Active control   1.69     2.06            1.00         --3.52    6.90
  QoL                   CCRT         Control          13.94    6.07            0.08         --1.40    29.29
                                     Active control   17.72    6.24            0.02         1.95      33.50
                        Control      Active control   3.78     6.58            1.00         --12.86   20.43

Based on estimated marginal means. Adjustment for multiple comparisons: Bonferroni.

### Sustained Attention {#S3.SS2.SSS1}

Findings of present study implied that there was time effect on sustained attention as well as a large-sized intervention by time interaction (*p* \< 0.001, $\eta_{p}^{2}$ = 0.29). Compared with baseline, sustained attention in CCRT and control groups improved at T1 (CCRT group: MD = 14.95, 95%CI = \[−25.18, −4.71\], SE = 3.72, *p* = 0.004; control group: MD = 10.54, 95%CI = \[−17.78, −3.31\], SE = 2.52, *p* = 0.006). In both groups the improvement remained stable at the follow-up (CCRT group: MD = −1.11, 95%CI = \[−4.42, 6.66\], SE = 2.01, *p* = 1.000; Control group: MD = −7.93, 95%CI = \[−1.18, 17.04\], SE = 3.17, *p* = 0.095) ([Figure 3](#F3){ref-type="fig"}). There was no effect of group on sustained attention.

![Cognitive functions and QoL. **(A)** Sustained attention, **(B)** Selective attention, **(C)** Divided attention, **(D)** Working memory, and **(E)** QoL at three time points. Error bars represent 95% confidence interval (CI). T0 = pre-intervention (week 0); T1 = post-intervention (week 8); T2 = 6-month follow-up (week 32).](fpsyg-10-01759-g003){#F3}

### Selective Attention {#S3.SS2.SSS2}

There was large-sized effect of time on selective attention score and a large-sized intervention by time interaction (*p* = 0.002, $\eta_{p}^{2}$ = 0.29). Selective attention in the CCRT group, but not in the other two groups, improved at T1 relative to baseline (MD = 15.98, 95%CI = \[4.03, 27.92\], SE = 4.35, *p* = 0.008) and this improvement remained stable at T2 (MD = −0.91, 95%CI = \[−1.87, 0.05\], SE = 0.35, *p* = 0.068) ([Figure 3](#F3){ref-type="fig"}). There was no effect of group on selective attention.

### Divided Attention {#S3.SS2.SSS3}

There was time effect on divided attention score also large-sized effect group by time interaction (*p* = 0.00, $\eta_{p}^{2}$ = 0.33), reflecting the lack of change in divided attention in control and active control groups (control group: T0 vs. T1: MD = −2.62, 95%CI = \[−7.18, 1.93\], SE = 1.58, *p* = 0.390; T1 vs. T2: MD = 1.27, 95%CI = \[−2.80, 5.35\], SE = 1.42, *p* = 1.000; active control group: T0 vs. T1: MD = 1.49, 95%CI = \[−2.77, 5.77\], SE = 1.45, *p* = 0.993; T1 vs. T2: MD = −2.59, 95%CI = \[−6.65, 1.46\], SE = 1.38, *p* = 0.281). In contrast, the CCRT improved divided attention score at T1 (MD = 6.66, 95%CI = \[3.34, 9.99\], SE = 1.21, *p* \< 0.001) and this improvement remained stable at T2 (MD = 6.40, 95%CI = \[−1.36, 14.18\], SE = 2.83, *p* = 0.124) ([Figure 3](#F3){ref-type="fig"}). There was no effect of group on divided attention.

### Working Memory {#S3.SS2.SSS4}

There were group and time effects on working memory score. There was large-sized effect group by time interaction (*p* \< 0.001, $\eta_{p}^{2}$ = 0.51). Pairwise comparisons confirmed that the CCRT led to improvement of working memory score at T1 relative to baseline (MD = 16.82, 95%CI = \[10.71, 22.92\], SE = 2.22, *p* \< 0.001) that was maintained at T2 (MD = −1.39, 95%CI = \[−6.13, 3.34\], SE = 1.72, *p* = 1.000) ([Figure 3](#F3){ref-type="fig"}). Pairwise comparison revealed that the working memory improvement in CCRT group was significantly greater than the working memory improvement in other two groups.

QoL Outcomes in Final Assessment {#S3.SS3}
--------------------------------

[Table 2](#T2){ref-type="table"} presents QoL mean scores corresponding to pre-, post-intervention and 6-month follow-up measurements. There were time and group effects on QoL and Large-sized effect group by time interaction (*p* = 0.001, $\eta_{p}^{2}$ = 0.31). Pairwise comparison confirmed that in CCRT and active control groups, but not in control group, QoL increased at T1 relative to T0 (CCRT group: MD = 25.41, 95%CI = \[14.93, 35.89\], SE = 3.81, *p* \< 0.001; active control group: MD = 8.62, 95%CI = \[0.51, 16.74\], SE = 2.76, *p* = 0.037). In both groups the improvement remained stable at T2 (CCRT group: MD = 0.65, 95%CI = \[−1.43, 2.74\], SE = 0.76, *p* = 1.000; active control group: MD = 0.61, 95%CI = \[−2.04, 3.27\], SE = 0.90, *p* = 1.000). However, pairwise comparison revealed that the QoL improvement in CCRT group was significantly greater than the QoL improvement in active control group (MD = 17.72, 95%CI = \[15.18, 36.55\], SE = 6.24, *p* = 0.023) ([Figure 3](#F3){ref-type="fig"}).

Correlation Between QoL Improvement and Cognitive Functions Enhancement {#S3.SS4}
-----------------------------------------------------------------------

All patients were included in the analysis of correlation [Table 4](#T4){ref-type="table"} shows relationship between QoL improvement and cognitive functions enhancement. Findings of current study shows significant correlation between QoL improvement and cognitive functions (except selective and divided attention) enhancement (sustained attention: Pearson's *r* = 0.34, *p* = 0.041; selective attention: Pearson's *r* = 0.32, *p* = 0.057; divided attention: Pearson's *r* = 0.30, *p* = 0.078; working memory: Pearson's *r* = 0.40, *p* = 0.016) ([Figure 4](#F4){ref-type="fig"}).

###### 

Summary of pre/follow-up correlation between QoL improvement and cognitive functions enhancement.

  **QoL improvement**   **Cognitive functions**                                                    
  --------------------- ------------------------- ------- ------ ------- ------ ------- ---------- -------
                        0.34^\*^                  0.041   0.32   0.057   0.30   0.078   0.40^\*^   0.016

\*

Correlation is significant at the 0.05 level.

![Pre/follow-up correlation between **(A)** QoL improvement and sustained attention enhancement, **(B)** QoL improvement and divided attention enhancement, and **(C)** QoL improvement and working memory enhancement.](fpsyg-10-01759-g004){#F4}

EM Algorithm {#S3.SS5}
------------

The EM algorithm is a general method for obtaining maximum likelihood estimates of parameters from incomplete data. The EM algorithm is based on the intuitive idea of estimating the missing value and iteratively re-estimating the parameters using the estimated missing values ([@B30]). Thirty-seven patients (51%) from three groups refused to complete the assessments at T2. Statistical analysis showed no significant difference in terms of demographic variables (*p* \> 0.05), clinical variables (*p* \> 0.05), cognitive functions (*p* \> 0.05), and QoL (*p* \> 0.05) measures between drop-out and remained patients. This indicates a random pattern of missing values.

In the EM algorithm there were main effects of time and group as well as the time by group interaction for all outcome scores (sustained attention: *p* \< 0.001, $\eta_{p}^{2}$ = 0.23; selective attention: *p* \< 0.001, $\eta_{p}^{2}$ = 0.27; divided attention: *p* \< 0.001, $\eta_{p}^{2}$ = 0.28; working memory: *p* \< 0.001, $\eta_{p}^{2}$ = 0.47; QoL: *p* \< 0.001, $\eta_{p}^{2}$ = 0.27) ([Table 5](#T5){ref-type="table"}).

###### 

Summary of repeated ANOVA on the entire patients (EM algorithm).

  **Components**        **CCRT group (*n* = 25)**   **Control group (*n* = 25)**   **Active Control group (*n* = 22)**   **Intervention F (*p*) \[$\eta_{p}^{2}$\]**   **Time F (*p*) \[$\eta_{p}^{2}$\]**   **Intervention × time *F* (*p*) \[$\eta_{p}^{2}$\]**                                                                   
  --------------------- --------------------------- ------------------------------ ------------------------------------- --------------------------------------------- ------------------------------------- ------------------------------------------------------ --------- --------- --------- ---------------- ---------------- ----------------
  Sustained attention   58.74                       71.20                          69.94                                 59.58                                         63.43                                 58.63                                                  65.25     64.34     63.07     3.24             11.86            10.52
                        (9.39)                      (7.32)                         (8.34)                                (10.88)                                       (10.43)                               (12.44)                                                (10.66)   (9.27)    (9.70)    (*p* = 0.045)    (*p* \< 0.001)   (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.08\]         \[0.14\]         \[0.23\]
  Selective attention   84.90                       98.95                          98.11                                 81.74                                         85.81                                 85.45                                                  82.72     81.64     81.24     8.21             20.52            13.22
                        (13.58)                     (0.93)                         (1.74)                                (16.44)                                       (12.80)                               (12.33)                                                (13.24)   (13.11)   (13.36)   (*p* = 0.001)    (*p* \< 0.001)   (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.19\]         \[0.22\]         \[0.27\]
  Divided Attention     86.86                       93.26                          98.33                                 89.21                                         86.19                                 87.82                                                  81.20     81.90     80.89     6.70             7.92             14.00
                        (11.77)                     (8.95)                         (3.36)                                (11.81)                                       (12.31)                               (10.13)                                                (16.04)   (12.85)   (12.62)   (*p* = 0.002)    (*p* = 0.01)     (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.16\]         \[0.10\]         \[0.28\]
  Working memory        70.24                       84.76                          83.49                                 70.74                                         68.78                                 66.07                                                  67.56     64.70     65.75     57.37            7.90             31.46
                        (6.94)                      (4.44)                         (5.33)                                (6.18)                                        (7.77)                                (6.58)                                                 (5.83)    (5.44)    (6.39)    (*p* \< 0.001)   (*p* = 0.001)    (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.62\]         \[0.10\]         \[0.47\]
  QoL                   53.48                       77.71                          77.18                                 49.70                                         60.56                                 60.79                                                  44.22     51.84     52.26     10.98            106.53           12.91
                        (21.12)                     (13.41)                        (11.65)                               (18.38)                                       (16.44)                               (12.84)                                                (18.29)   (14.62)   (13.01)   (*p* \< 0.001)   (*p* \< 0.001)   (*p* \< 0.001)
                                                                                                                                                                                                                                                                                                  \[0.24\]         \[0.60\]         \[0.27\]

Values represent mean scores (SD and

η

p

2

are between parenthesis and brackets respectively). Significant time by group interaction was observed. T0 = pre-intervention (week 0); T1 = post-intervention (week 8); T2 = 6-month follow-up (week 32).

Discussion {#S4}
==========

The purpose of this study was to examine the efficacy of a CCRT in a group of patients after CABG surgery. We sought to find whether using cognitive rehabilitation could improve the QoL in this group of patients. According to what we have found, significant QoL improvement was detected in patients who received CCRT compared to the other two groups. In other words, our results support the beneficial effects of incorporation of cognitive rehabilitation in the RCR. This is one of the first studies to demonstrate the effectiveness of using cognitive rehabilitation after CABG surgery.

The positive association between cognitive rehabilitation and the improved QoL has been previously reported in patients with MS, Parkinson's disease and brain tumors ([@B39]; [@B50]; [@B43]; [@B22]). But less is known about the patients who receive CABG surgery, while a large body of evidence reports postoperative cognitive deficits in this group of patients ([@B66]; [@B25]; [@B45]; [@B10]; [@B21]).

We used a computerized cognitive rehabilitation program for one group of patients which resulted in improved cognitive functions in terms of sustained, selective, divided attention and working memory. This result extends the previous work by [@B17] by using a larger sample size. In our study, those patients who receive CCRT within 2 months, outperformed the other two groups on different tests of attention and working memory. This suggests that the applied program was an efficient cognitive training for our sample that could help them to engage and disengage their attention properly in the context of real life.

Moreover, a significant improvement in sustained attention was found for our control group but not for the active control group. This shows that the sham version used for the active control group, didn't provide any targeted training.

Consistent with previous studies, improved cognitive functions is associated with better QoL ([@B19]; [@B53]; [@B78]). This is because cognitive impairments can reduce daily function and social interactions of individuals and make them more dependent on others for their everyday activities ([@B34]; [@B46]; [@B48]; [@B65]). Therefore, it is no surprising that QoL was reported higher by CCRT group compared to the other two groups. While the active control group achieved the same positive results as the CCRT group, the CCRT group rated QoL significantly better than the active control group. With regard to the possibility of chance findings due to the high rate of drop-out at follow-up, it is very important for future investigations to carry out the similar study with larger sample size.

Taken together, these results suggest the benefits of adding cognitive rehabilitation as an adjunct therapeutic intervention for patients undergoing CABG surgery to ameliorate postoperative cognitive deficits and increase QoL. These results offer a new line of research for developing a new cognitive rehabilitation tool that specifically targets postoperative cognitive deficits that are commonly observed in this group.

Our study has several strengths. We have used a 3-arm interventional design that allowed us to compare three different conditions. There was also a 6-month follow-up to track the training benefits over time. But, there are also some limitations that should be noted. First, the CCRT used in this study was focused on attention and working memory, so further studies would benefit from targeting other cognitive functions including executive functions ([@B59]). Second, we didn't consider the far transfer effects of training in real life situations (e.g., managing household, managing medications), thus we suggest to use relevant measures for better understanding the effects of cognitive rehabilitation. Another limitation of this study is related to the high rate of drop-out at 6-month follow-up that should be considered and controlled in future studies. Finally, our limitation to access patient's medical record was a barrier to consider them in our analysis, so including these data in future investigations allows detailed comparison of the baseline characteristics.

In conclusion, the results obtained in this study with regard to improvement of cognitive functions as well as QoL in patients after CABG surgery, may follow valuable clinical implications for those who provide health care services for this group of patients.

Ethics Statement {#S5}
================

This study was carried out in accordance with the recommendations of Ethics Committee of the Iranian Ministry of Health (reference number: IR.ut.Rec.1395029) with written informed consent from all patients. All patients gave written informed consent in accordance with the Declaration of Helsinki. The protocol was approved by the Iranian Registry of Clinical Trials, IRCT ID: IRCT2017022132704N1 (<http://www.irct.ir/trial/25408>).

Author Contributions {#S6}
====================

HE, SA, TR, HM, and SE were responsible for the conception and design of the study. SA and SE were responsible for data collection and for evaluations and treatments. MH was responsible for data analysis. TR and SA contributed to the interpretation of data. SA wrote the manuscript, which was critically revised by HE and TR. All authors have approved the final version of the manuscript.

Conflict of Interest Statement {#conf1}
==============================

HE and TR designed the Maghzineh architecture and games. HM is the CEO of Pars Cognition, a small spin off company in the University of Tehran incubator. The remaining authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

**Funding.** SA had received supports from the Cognitive Science and Technologies Council (CSTS) of Iran and the University of Tehran College of Farabi for collaborating in this Clinical Trial.

We acknowledge the Tehran Heart Center Hospital for use of their facilities. We are greatly thankful to the study participants for their interest and cooperation in the project.

[^1]: Edited by: Federica Scarpina, Italian Auxological Institute (IRCCS), Italy

[^2]: Reviewed by: Berta Rodrigues Maia, Catholic University of Portugal, Portugal; Tobias Kube, Harvard Medical School, United States

[^3]: This article was submitted to Psychology for Clinical Settings, a section of the journal Frontiers in Psychology
